がんワクチンの世界市場レポート 2024

がんワクチンの市場規模は、今後数年間で急速に成長すると予想されます。 2028年には13.9%の年間複合成長率（CAGR）で138億9,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、いくつかの重要な要因に遡ることができます。これらには、がんワクチンを含む併用療法の利用、製薬会社から流入する投資の拡大、新しいバイオマーカーの出現、個別化ワクチンの開発、ワクチン接種プログラムの継続的拡大が含まれます。

世界のがん症例の増加が予測されており、予測期間を通じてがんワクチン市場の拡大が促進されると予想されます。米国がん協会の2022年 1月の報告書によると、米国だけで推定190万人が新たにがんと診断され、609,360人ががん関連で死亡すると予想されています。このがん罹患率の急増、特に肺がん、前立腺がん、腸がん、女性乳がんなどの顕著な種類のがんの罹患率の急増は、合計で世界中の新規症例の43%を占めており、今後数年間でがんワクチンの需要が高まることが予想されます。

がんワクチン市場で予想される成長は、研究開発努力に対する政府の割り当ての拡大によって推進されています。がんの調査と治療の進歩に役立つ政府の資金は、科学的取り組み、医療インフラ、ケアへのアクセスの改善に資金を提供することで極めて重要な役割を果たしています。国立がん研究所は、2023年 9月に米国議会から73億米ドルの予算（前年比4億800万米ドル増）を受け取りましたが、これはこの傾向を反映しています。研究開発に対する政府支援の流入は、がんワクチン市場の上昇軌道に大きく貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のがんワクチン市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• がん予防ワクチン
• 治療用がんワクチン
• 世界のがんワクチン市場、技術別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 樹状細胞（DC）がんワクチン
• 組換えがんワクチン
• 抗原/アジュバントがんワクチン
• 全細胞がんワクチン
• ウイルスベクターおよびDNAがんワクチン
• 世界のがんワクチン市場、がんタイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 前立腺
• 子宮頸部
• 結腸直腸
• 喉
• その他のがんタイプ
• 世界のがんワクチン市場、最終用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• がん治療センター
• 研究機関

第7章 地域および国の分析

• 世界のがんワクチン市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のがんワクチン市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がんワクチン市場の競合情勢
• がんワクチン市場の企業プロファイル
  • GlaxoSmithKline plc
  • Merck &Co. Inc.
  • Aduro Biotech Inc.
  • AstraZeneca PLC
  • Dendreon

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

Cancer vaccines encompass preventive and therapeutic vaccinations intended to aid the body in preventing illness and treating cancer. These vaccines aim to instruct the immune system to identify and eliminate harmful microbes and cells.

They are broadly categorized into preventive and therapeutic cancer vaccines. Therapeutic vaccines assist the immune system in recognizing viruses or malignant cells. Various technologies, including dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, viral vectors, and DNA cancer vaccines, are employed across different types of cancers like prostate, cervical, colorectal, throat, and others. These innovations operate within sectors like cancer treatment centers and research institutes.

The cancer vaccines market research report is one of a series of new reports from The Business Research Company that provide cancer vaccines market statistics, such as cancer vaccines industry global market size, regional shares, competitors with a cancer vaccines market share, detailed cancer vaccines market segments, market trends and opportunities, and any other information you may require to thrive in the cancer vaccines industry. This cancer vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer vaccines market size has grown rapidly in recent years. It will grow from $7.22 billion in 2023 to $8.25 billion in 2024 at a compound annual growth rate (CAGR) of 14.3%. During the historic period, the expansion observed in this field was propelled by several factors. These include the heightened occurrence of cancer, greater recognition and understanding of cancer vaccines, an increasing array of approved cancer vaccines, mounting evidence supporting their effectiveness, and substantial governmental backing for research and development initiatives.

The cancer vaccines market size is expected to see rapidly grown in the next few years. It will grow to $13.89 billion in 2028 at a compound annual growth rate (CAGR) of 13.9%. The anticipated growth in the forecast period can be traced back to several key factors. These encompass the utilization of combination therapies involving cancer vaccines, amplified investments pouring in from pharmaceutical companies, the emergence of new biomarkers, the development of personalized vaccines, and the continuous expansion of vaccination programs.

The projected escalation in global cancer cases is anticipated to fuel expansion within the cancer vaccines market throughout the forecast period. As per the American Cancer Society's January 2022 report, an estimated 1.9 million new cancer diagnoses and 609,360 cancer-related deaths are expected in the US alone. This surge in cancer prevalence, notably in prominent types like lung, prostate, bowel, and female breast cancer, collectively accounting for 43% of new cases worldwide, is expected to spur demand for cancer vaccines in the years ahead.

Anticipated growth in the cancer vaccines market is driven by amplified government allocations for research and development efforts. Government funding, instrumental in advancing cancer research and treatment, plays a pivotal role by financing scientific endeavors, medical infrastructure, and improved access to care. The National Cancer Institute, receiving a $7.3 billion budget in September 2023 from the United States Congress-an increase of $408 million from the previous year-reflects this trend. This influx of government support for research and development significantly contributes to the upward trajectory of the cancer vaccines market.

Companies within the cancer vaccines sector are progressively investing in preventive or prophylactic vaccine development aimed at averting cancer incidence. Prophylactic vaccines, intended to bolster immunity, introduce antigens into the body. Notably, cervical cancer ranks as the second-most common cancer among women globally, prompting the availability of three HPV vaccines for prophylactic use. Merck's Gardasil and Gardasil 9, along with GSK's Cervarix, collectively provide protection against HPV types responsible for a substantial majority of cervical cancers, including HPV 16, 18, and additional oncogenic types.

Key players in the cancer vaccines industry are directing their focus towards introducing quadrivalent vaccines to optimize market revenue. These vaccines offer protection against multiple strains of specific viruses or bacteria. Serum Institute of India's launch of CERVAVAC in January 2023 exemplifies this trend, presenting the first indigenous cervical cancer vaccine designed to combat HPV types 16, 18, 6, and 11 accounting for a significant portion of cervical cancers. Administered in either two or three doses depending on age, this vaccine aims to maximize prevention within the specified demographic.

In March 2022, NEC OncoImmunity (NOI), a biotechnology company headquartered in Norway, completed the acquisition of neoantigen vaccine development assets from Vaximm AG, a Switzerland-based biotech firm. The financial details of this transaction were not disclosed. This strategic acquisition is anticipated to empower NOI in advancing its AI-driven and personalized treatment strategies tailored for combating cancer. Vaximm AG specializes in manufacturing vaccines and T-cell immunotherapies designed to aid patients battling cancer.

Major companies operating in the cancer vaccines market include GlaxoSmithKline PLC, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

North America was the largest region in the cancer vaccines market in 2023. The regions covered in the cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cancer vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The cancer vaccines market consists of sales of Bacillus calmette-guerin, Sipuleucel-T, and Human Papillomavirus (HPV) vaccines. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Vaccines Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer vaccines? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Preventive Cancer Vaccines; Therapeutic Cancer Vaccines
• 2) By Technology: Dendritic Cells (DC) Cancer Vaccines; Recombinant Cancer Vaccines; Antigen/Adjuvant Cancer Vaccines; Whole Cell Cancer Vaccines; Viral Vector & DNA Cancer Vaccines
• 3) By Cancer Type: Prostate; Cervical; Colorectal; Throat; Other Cancer Types
• 4) By End-User: Cancer Treatment Centers; Research Institutes
• Companies Mentioned: GlaxoSmithKline plc; Merck & Co. Inc.; Aduro Biotech Inc.; AstraZeneca PLC; Dendreon Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Vaccines Market Characteristics

3. Cancer Vaccines Market Trends And Strategies

4. Cancer Vaccines Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Cancer Vaccines Market Size and Growth

• 5.1. Global Cancer Vaccines Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Cancer Vaccines Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Cancer Vaccines Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cancer Vaccines Market Segmentation

• 6.1. Global Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines
• 6.2. Global Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Dendritic Cells (DC) Cancer Vaccines
• Recombinant Cancer Vaccines
• Antigen/Adjuvant Cancer Vaccines
• Whole Cell Cancer Vaccines
• Viral Vector & DNA Cancer Vaccines
• 6.3. Global Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Prostate
• Cervical
• Colorectal
• Throat
• Other Cancer Types
• 6.4. Global Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Cancer Treatment Centers
• Research Institutes

7. Cancer Vaccines Market Regional And Country Analysis

• 7.1. Global Cancer Vaccines Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Cancer Vaccines Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cancer Vaccines Market

• 8.1. Asia-Pacific Cancer Vaccines Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cancer Vaccines Market

• 9.1. China Cancer Vaccines Market Overview
• 9.2. China Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cancer Vaccines Market

• 10.1. India Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cancer Vaccines Market

• 11.1. Japan Cancer Vaccines Market Overview
• 11.2. Japan Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cancer Vaccines Market

• 12.1. Australia Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cancer Vaccines Market

• 13.1. Indonesia Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cancer Vaccines Market

• 14.1. South Korea Cancer Vaccines Market Overview
• 14.2. South Korea Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cancer Vaccines Market

• 15.1. Western Europe Cancer Vaccines Market Overview
• 15.2. Western Europe Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cancer Vaccines Market

• 16.1. UK Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cancer Vaccines Market

• 17.1. Germany Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cancer Vaccines Market

• 18.1. France Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cancer Vaccines Market

• 19.1. Italy Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cancer Vaccines Market

• 20.1. Spain Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cancer Vaccines Market

• 21.1. Eastern Europe Cancer Vaccines Market Overview
• 21.2. Eastern Europe Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cancer Vaccines Market

• 22.1. Russia Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cancer Vaccines Market

• 23.1. North America Cancer Vaccines Market Overview
• 23.2. North America Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cancer Vaccines Market

• 24.1. USA Cancer Vaccines Market Overview
• 24.2. USA Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cancer Vaccines Market

• 25.1. Canada Cancer Vaccines Market Overview
• 25.2. Canada Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cancer Vaccines Market

• 26.1. South America Cancer Vaccines Market Overview
• 26.2. South America Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cancer Vaccines Market

• 27.1. Brazil Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cancer Vaccines Market

• 28.1. Middle East Cancer Vaccines Market Overview
• 28.2. Middle East Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cancer Vaccines Market

• 29.1. Africa Cancer Vaccines Market Overview
• 29.2. Africa Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Cancer Vaccines Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cancer Vaccines Market Competitive Landscape And Company Profiles

• 30.1. Cancer Vaccines Market Competitive Landscape
• 30.2. Cancer Vaccines Market Company Profiles
  • 30.2.1. GlaxoSmithKline plc
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Merck & Co. Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Aduro Biotech Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AstraZeneca PLC
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Dendreon
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Cancer Vaccines Market Competitive Benchmarking

32. Global Cancer Vaccines Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Cancer Vaccines Market

34. Cancer Vaccines Market Future Outlook and Potential Analysis

• 34.1 Cancer Vaccines Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Cancer Vaccines Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Cancer Vaccines Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer